Book contents
- Medication-Resistant Epilepsy
- Medication-Resistant Epilepsy
- Copyright page
- Dedication
- Contents
- Contributors
- Chapter 1 The Natural History of Epilepsy
- Chapter 2 Challenges in Identifying Medication-Resistant Epilepsy
- Chapter 3 International League Against Epilepsy’s Definition of Medication-Resistant Epilepsy
- Chapter 4 The Economic Impact of Medication-Resistant Epilepsy
- Chapter 5 Social Consequences of Medication-Resistant Epilepsy
- Chapter 6 Mortality and Morbidity of Medication-Resistant Epilepsy
- Chapter 7 Models for Medication-Resistant Epilepsy
- Chapter 8 Neurobiology of Medication-Resistant Epilepsy
- Chapter 9 Genetic Causes of Medication-Resistant Epilepsy
- Chapter 10 Malformations of Cortical Development as Causes of Medication-Resistant Epilepsy
- Chapter 11 Hippocampal Sclerosis as a Cause of Medication-Resistant Epilepsy
- Chapter 12 Autoimmune Causes of Medication-Resistant Epilepsy
- Chapter 13 Medication-Resistant Epilepsy Syndromes in Children
- Chapter 14 Medication-Resistant Epilepsy in Adults
- Chapter 15 Approach to the Treatment of Medication-Resistant Epilepsy
- Chapter 16 Pharmacotherapy for Medication-Resistant Epilepsy
- Chapter 17 Reproductive Health for Women with Medication-Resistant Epilepsy
- Chapter 18 Resective Surgery for Medication-Resistant Epilepsy
- Chapter 19 Ablative Surgery for Medication-Resistant Epilepsy
- Chapter 20 Stimulation Treatment for Medication-Resistant Epilepsy
- Chapter 21 Diet Therapy for Medication-Resistant Epilepsy
- Chapter 22 Botanical Treatments for Medication-Resistant Epilepsy
- Chapter 23 Psychiatric Comorbidities in Medication-Resistant Epilepsy
- Index
- References
Chapter 6 - Mortality and Morbidity of Medication-Resistant Epilepsy
Published online by Cambridge University Press: 20 August 2020
- Medication-Resistant Epilepsy
- Medication-Resistant Epilepsy
- Copyright page
- Dedication
- Contents
- Contributors
- Chapter 1 The Natural History of Epilepsy
- Chapter 2 Challenges in Identifying Medication-Resistant Epilepsy
- Chapter 3 International League Against Epilepsy’s Definition of Medication-Resistant Epilepsy
- Chapter 4 The Economic Impact of Medication-Resistant Epilepsy
- Chapter 5 Social Consequences of Medication-Resistant Epilepsy
- Chapter 6 Mortality and Morbidity of Medication-Resistant Epilepsy
- Chapter 7 Models for Medication-Resistant Epilepsy
- Chapter 8 Neurobiology of Medication-Resistant Epilepsy
- Chapter 9 Genetic Causes of Medication-Resistant Epilepsy
- Chapter 10 Malformations of Cortical Development as Causes of Medication-Resistant Epilepsy
- Chapter 11 Hippocampal Sclerosis as a Cause of Medication-Resistant Epilepsy
- Chapter 12 Autoimmune Causes of Medication-Resistant Epilepsy
- Chapter 13 Medication-Resistant Epilepsy Syndromes in Children
- Chapter 14 Medication-Resistant Epilepsy in Adults
- Chapter 15 Approach to the Treatment of Medication-Resistant Epilepsy
- Chapter 16 Pharmacotherapy for Medication-Resistant Epilepsy
- Chapter 17 Reproductive Health for Women with Medication-Resistant Epilepsy
- Chapter 18 Resective Surgery for Medication-Resistant Epilepsy
- Chapter 19 Ablative Surgery for Medication-Resistant Epilepsy
- Chapter 20 Stimulation Treatment for Medication-Resistant Epilepsy
- Chapter 21 Diet Therapy for Medication-Resistant Epilepsy
- Chapter 22 Botanical Treatments for Medication-Resistant Epilepsy
- Chapter 23 Psychiatric Comorbidities in Medication-Resistant Epilepsy
- Index
- References
Summary
There is significant mortality and morbidity associated with medication-resistant epilepsy, with attendant major impact on physical, psychological, emotional, socioeconomic and other aspects of the lives of persons with epilepsy and their families. Emphasis on these issues is an imperative that is often underappreciated or overlooked, with subsequent far-reaching consequences that may be avoidable. Young adults with active epilepsy from low socioeconomic groups are more likely to die prematurely, and important contributors to mortality include comorbid disorders, such as cardiovascular diseases, cancer and unintentional injuries [1]. Notably, deaths from direct epilepsy-related causes occur in about 10% of cases, but are likely to be underestimated [2]. In this chapter, we examine the risks, types, impact and governing factors of mortality and morbidity in the population of persons with intractable epilepsy. We also discuss the commonest category of death in the intractable population – sudden unexpected death in epilepsy (SUDEP).
- Type
- Chapter
- Information
- Medication-Resistant EpilepsyDiagnosis and Treatment, pp. 39 - 50Publisher: Cambridge University PressPrint publication year: 2020